Industry

Ferring receives health Canada approval for REBYOTA

The approval is major step forward in the fight against recurrent C. diff infection.

BiomX Secures $12 Million to Drive Phage Therapy Advancements for Cystic Fibrosis Treatment

Financing will also support analysis of real-world evidence in people with CF to explore the relationship between P. aeruginosa reduction and clinical outcomes.

Seres Therapeutics takes key step toward SER-155 approval with positive FDA feedback on bloodstream infection prevention

Seres Therapeutics, a leader in the live biotherapeutics space, has received pivotal feedback from the U.S. Food and Drug Administration (FDA) regarding the development of its lead investigational treatment, SER-155,…

Flow VIT® Test Kits: The Next Step in Specific Probiotic Enumeration

In July 2024, the journal Frontiers in Microbiology presented a groundbreaking method that overcomes this hurdle: the Flow-FISH method.

Probiotic intervention in the gut–prostate axis with novaPROX combo: insights from an in vitro study

The study published on Foods Journal researched the mechanisms of action of Probionova's novaPROX product using a 3D intestinal barrier model and a co-culture prostatic model.

The evolution of REBYOTA: milestones in microbiome-based therapeutics

On the second anniversary of its launch, Ferring Pharmaceuticals’ REBYOTA remains a landmark innovation in the prevention of recurrent Clostridioides difficile.

Innovative Potential of Lonza’s Capsugel® Enprotect® Capsules in Targeted Live Biotherapeutics and Pharmaceutical Applications

Lonza's capsules ensures targeted intestinal delivery enhancing stability and therapeutic efficacy for LBPs and pharmaceutical applications.

Unlocking the hidden world of the small intestine: a new frontier in microbiome science

Cmbio announces a strategic partnership with Nimble Science to deliver first in class high-quality, multi-omic data insights from the small intestine.

Cmbio® strengthens its digital biology platform with acquisition of Eagle Genomics’ assets

The acquisition will enhance its ability to address the needs of a growing market, empowering researchers and industries worldwide.

Revolutionizing treatment for Acute Graft-versus-Host Disease: MaaT Pharma’s groundbreaking Phase 3 results

The live biotherapeutics market is forecasted to exceed $4 billion by 2030, driven by advancements like MaaT013.

Subscribe to MicrobiomePost newsletter

Take full advantage of MicrobiomePost‘s features.

Scroll to Top